Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a stock to watch today. At current price of $8, the shares have already added 0.35 points (4.58% higher) from its previous close of $7.65. The stock sets an active trading volume day with a reported 116797 contracts so far this session. MRSN shares had a relatively better volume day versus average trading capacity of 402.55 thousand shares, but with a 46.87 million float and a 11.84% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for MRSN stock indicates that the average analyst price target is $11.25 per share. This means the stock has a potential increase of 40.63% from where the MRSN share price has been trading recently.
During the recent trading session for Mersana Therapeutics, Inc. (NASDAQ:MRSN), the company witnessed their stock rise $1.3 over a week and surge $0.28 from the price 20 days ago. When compared to their established 52-week high of $8.93, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 01/17/20. The recent low of $1.32 stood for a -10.41% since 04/11/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Mersana Therapeutics, Inc., the two-week RSI stands at 61.73. This figure suggests that MRSN stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current MRSN readings is similarly very revealing as it has a stochastic reading of 77.92% at this stage. This figure means that MRSN share price today is being oversold.
Technical chart claims that Mersana Therapeutics, Inc. (MRSN) would settle between $8.04/share to $8.42/share level. However, if the stock price goes below the $7.43 mark, then the market for Mersana Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $7.2 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.46. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at H.C. Wainwright lifted target price for shares of MRSN but were stick to Buy recommendation for the stock in their opinion released on January 21. The price target has been raised from $7 to $12. JP Morgan analysts have lowered their rating of Mersana Therapeutics, Inc. (NASDAQ:MRSN) stock from Neutral to Underweight in a separate flash note issued to investors on March 11. Analysts at Leerink Partners released an upgrade from Mkt Perform to Outperform for the stock, in a research note that dated back to November 14.
MRSN equity has an average rating of 1.83, with the figure leaning towards a bullish end. 6 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 6 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 5 analysts rated Mersana Therapeutics, Inc. (NASDAQ:MRSN) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Mersana Therapeutics, Inc. (MRSN)’s current-quarter revenues are projected to climb by nearly -75.6% to hit $290000, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 299.8% from $10.59 million to a noteworthy $42.36 million. At the other end of the current quarter income statement, Mersana Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 60.8% to hit $-0.38 per share. For the fiscal year, MRSN’s earnings are projected to climb by roughly 77.4% to hit $-0.63 per share.